| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
1Correspondence: Medicine Branch, NCI, NIH, Bldg. 10, Room 13 N 226, Bethesda, MD, 20892, USA. E-mail: mikhailb{at}box-m.nih.gov
Increasing the complexity of their models, p53s are stabilized either in order to function (wt p53) or due to the loss of function (mutant p53) with acquiring a mysterious prion-like ability to drive the normal p53 into the abnormal conformation to gain new functions. As already recognized, the loss of trans-activating function leads to a stabilization of mutant p53 because of the disappearance of the p53-inducible proteins, which otherwise directly (Mdm-2) or indirectly (p21) target p53 for degradation. Simplifying further, I will discuss that the loss of function results in a dominant-negative effect and gain-of-function (a dominant-positive effect). Thus, mutant p53 lacking trans-activation function nevertheless may retain the ability to repress transcription due to its competition with numerous transcription factors for their coactivators. When mutant p53 competes with wt p53, the inhibition of the wt p53-dependent transcription is perceived as a dominant-negative effect. Just like trans-repression, a dominant-negative effect requires an excess of p53 and, therefore, a ‘dominant’-negative effect is not dominant. Furthermore, the stabilization of an endogenous mt p53 due to the loss of wt functions cannot occur in the presence of the wt p53 allele. Given the inability of mutant p53 to accumulate in the presence of wt p53, a dominant-negative effect does not naturally occur and, not surprisingly, heterozygous mt/wt cells are rare. The detection of a dominant-negative effect simply indicates that mutant p53 indeed has lost its function. Last, since mutant p53 loses some or most but not all activities and accumulates in the absence of wt allele, gain-of-function can be considered as an exaggeration of the remaining functions. Applications to cancer therapy are discussed.—Blagosklonny, M. V. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect.
Key Words: prion • dysfunction • cancer therapy • trans-activating function
This article has been cited by other articles:
|
|
 |
|
  S. A. Danziger, J. Zeng, Y. Wang, R. K. Brachmann, and R. H. Lathrop Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants Bioinformatics, July 1, 2007; 23(13): i104 - i114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Dearth, H. Qian, T. Wang, T. E. Baroni, J. Zeng, S. W. Chen, S. Y. Yi, and R. K. Brachmann Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers Carcinogenesis, February 1, 2007; 28(2): 289 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ceruti, A. Mazzola, and M. P. Abbracchio Proteasome Inhibitors Potentiate Etoposide-Induced Cell Death in Human Astrocytoma Cells Bearing a Mutated p53 Isoform J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1424 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gaasenbeek, K. Howarth, A. J. Rowan, P. A. Gorman, A. Jones, T. Chaplin, Y. Liu, D. Bicknell, E. J. Davison, H. Fiegler, et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res., April 1, 2006; 66(7): 3471 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Muller, P. Ceskova, and B. Vojtesek Hsp90 Is Essential for Restoring Cellular Functions of Temperature-sensitive p53 Mutant Protein but Not for Stabilization and Activation of Wild-type p53: IMPLICATIONS FOR CANCER THERAPY J. Biol. Chem., February 25, 2005; 280(8): 6682 - 6691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. O'Farrell, P. Ghosh, N. Dobashi, C. Y. Sasaki, and D. L. Longo Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression Cancer Res., November 15, 2004; 64(22): 8199 - 8207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Pohnke, T. Schneider-Merck, J. Fahnenstich, R. Kempf, M. Christian, K. Milde-Langosch, J. J. Brosens, and B. Gellersen Wild-Type p53 Protein Is Up-Regulated upon Cyclic Adenosine Monophosphate-Induced Differentiation of Human Endometrial Stromal Cells J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5233 - 5244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Girnita, A. Girnita, and O. Larsson Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor PNAS, July 8, 2003; 100(14): 8247 - 8252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Gurova, O. W. Rokhlin, A. V. Budanov, L. G. Burdelya, P. M. Chumakov, M. B. Cohen, and A. V. Gudkov Cooperation of Two Mutant p53 Alleles Contributes to Fas Resistance of Prostate Carcinoma Cells Cancer Res., June 1, 2003; 63(11): 2905 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Yoon, C.-S. Lee, and G. P. Pfeifer Simulated sunlight and benzo[a]pyrene diol epoxide induced mutagenesis in the human p53 gene evaluated by the yeast functional assay: lack of correspondence to tumor mutation spectra Carcinogenesis, January 1, 2003; 24(1): 113 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Strano, G. Fontemaggi, A. Costanzo, M. G. Rizzo, O. Monti, A. Baccarini, G. Del Sal, M. Levrero, A. Sacchi, M. Oren, et al. Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities J. Biol. Chem., May 17, 2002; 277(21): 18817 - 18826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Karamouzis, V. G. Gorgoulis, and A. G. Papavassiliou Transcription Factors and Neoplasia: Vistas in Novel Drug Design Clin. Cancer Res., May 1, 2002; 8(5): 949 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Nicholls, K. G. McLure, M. A. Shields, and P. W. K. Lee Biogenesis of p53 Involves Cotranslational Dimerization of Monomers and Posttranslational Dimerization of Dimers. IMPLICATIONS ON THE DOMINANT NEGATIVE EFFECT J. Biol. Chem., April 5, 2002; 277(15): 12937 - 12945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kamiya, M. Puzianowska-Kuznicka, P. McPhie, J. Nauman, S.-y. Cheng, and A. Nauman Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma Carcinogenesis, January 1, 2002; 23(1): 25 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bai and J. L. Merchant ZBP-89 Promotes Growth Arrest through Stabilization of p53 Mol. Cell. Biol., July 15, 2001; 21(14): 4670 - 4683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sigal and V. Rotter Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome Cancer Res., December 1, 2000; 60(24): 6788 - 6793. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
